What is Aquestive Therapeutics Profitability Rank?
Aquestive Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Aquestive Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -29.62%. As of today, Aquestive Therapeutics's Piotroski F-Score is 5.
Competitive Comparison of Aquestive Therapeutics's Profitability Rank
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's Profitability Rank Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Profitability Rank falls into.
Aquestive Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Aquestive Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Aquestive Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Aquestive Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Aquestive Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
| Carl N Kraus |
officer: Chief Medical Officer |
C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709 |
| Stephen Wargacki |
officer: SVP, Research & Development |
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Cassie Jung |
officer: SVP, Operations |
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Kenneth Truitt |
officer: Chief Medical Officer |
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Timothy E Morris |
director |
ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
| Peter E. Boyd |
officer: SVP-Operations/Value Delivery |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Lori J Braender |
officer: SVP, General Counsel |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Daniel Barber |
officer: SVP-Chief Strategy/Dev Officer |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Alexander Mark Schobel |
director, officer: Chief Innovation/Tech Officer |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Julie Krop |
director |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Marco Taglietti |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Toth A Ernest Jr |
officer: Interim CFO |
|
| John T. Maxwell |
officer: SVP-Chief Financial Officer |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| Keith J Kendall |
director, officer: President and CEO |
30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
| James S Scibetta |
director |
C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your